Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Cytokinetics

    - PMLiVE

    Cytokinetics shares positive phase 3 results for aficamten in heart disease

    Up to one in 500 people in the UK and US are living with hypertrophic cardiomyopathy

    - PMLiVE

    Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

    The neurodegenerative disease affects approximately 27,000 people in the US

    - PMLiVE

    FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

    BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

    - PMLiVE

    Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

    Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death

    - PMLiVE

    Amgen agrees to take Cytokinetics’ heart failure drug into phase III

    Phase II results showed significant cardiac function benefit and no adverse safety signals

    Biogen Idec building

    Biogen buys into Ionis’ nusinersen after positive phase III trial

    Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

    Astellas forges $675m muscle alliance with Cytokinetics

    Extendscollaboration to include neuromuscular diseases

    - PMLiVE

    Amgen drug misses endpoint in acute heart failure trial

    Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links